Skip to main content

Table 2 Baseline patient characteristics in the pre- and post-PSM cohort

From: Propensity score matching analysis of a phase II study on simultaneous modulated accelerated radiation therapy using helical tomotherapy for nasopharyngeal carcinomas

  Before PSM After PSM
Characteristics P67.5
(n = 158)
P70
(n = 216)
P* P67.5
(n = 148)
P70
(n = 148)
P*
Gender    0.537    0.896
 Male 114 (72.2%) 162 (75.0%)   108 (73.0%) 107 (72.3%)  
 Female 44 (27.8%) 54 (25.0%)   40 (27.0%) 41 (27.7%)  
Age (years)    0.434    0.444
 Median (range) 47 (15–75) 44 (10–81)   47 (15–75) 45 (10–81)  
 Mean (SD) 45.5 (13.5) 44.4 (13.9)   45.7 (13.0) 44.3 (13.8)  
T stage    0.485    0.822
 1 41 (25.9%) 63 (29.2%)   41 (27.7%) 46 (31.1%)  
 2 49 (31.0%) 71 (32.9%)   48 (32.4%) 41 (27.7%)  
 3 43 (27.2%) 44 (20.4%)   34 (23.0%) 34 (23.0%)  
 4 25 (15.8%) 38 (17.6%)   25 (16.9%) 27 (18.2%)  
N stage    0.014    0.985
 0 21 (13.3%) 46 (21.3%)   21 (14.2%) 22 (14.9%)  
 1 50 (31.6%) 85 (39.4%)   50 (33.8%) 51 (34.5%)  
 2 77 (48.7%) 71 (32.9%)   68 (45.9%) 65 (43.9%)  
 3 10 (6.3%) 14 (6.5%)   9 (6.1%) 10 (6.8%)  
Clinical stage    0.017    0.829
 I 7 (4.4%) 16 (7.4%)   7 (4.7%) 8 (5.4%)  
 II 36 (22.8%) 72 (33.3%)   36 (24.3%) 39 (26.4%)  
 III 80 (50.6%) 76 (35.2%)   71 (48.0%) 63 (42.6%)  
 IVa 35 (22.2%) 52 (24.1%)   34 (23.0%) 38 (25.7%)  
  1. Abbreviation: PSM Propensity score matching
  2. *P-values were calculated using the Pearson χ2 test